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with non-specific symptoms and signs of
cancer referred to a fast track cancer patient
pathway; a retrospective cohort study
Sara Falk Jørgensen1,2*, Pernille Ravn1,2, Søren Thorsen1 and Signe Westring Worm3
Abstract
Background: In 2012 a new cancer patient pathway for patients with non-specific symptoms and signs of cancer
(NSSC-CPP) was introduced in Denmark. Limited information is available about the patients referred to the NSSC-CPP
and the investigational course. The aim was to describe the population and the investigational course, estimate the
prevalence of cancer and one-year mortality, and identify factors associated with a subsequent cancer diagnosis in
patients referred to the NSSC-CPP.
Method: This cohort study included patients with at least one visit at the NSSC-CPP at North Zealand Hospital in
Denmark (NOH) from October 1st 2013 to September 30th 2014. Data was based on retrospective reviews of the
patient files. Logistic regression identified factors associated with a subsequent cancer diagnosis. Multivariate analyses
were adjusted by age, gender, smoking status and alcohol consumption. Kaplan-Meier survival plots were made at
one-year follow-up.
Results: Eight hundred twenty-five patients were included with a median age of 67 years, 47.4% were male. Prevalence
of cancer within one year was 16.7% (138/825). 70.3% (97/138) were solid cancers and 29.7% (41/138) were
haematological cancers. During the investigational course 76.7% went through advanced diagnostic imaging (ultrasound,
CT, FDG-PET/CT or MRI). Anaemia (OR1.63 CI1.02–2.60), leucocytosis (OR 2.06 CI 1.34–3.15), thrombocytopenia (OR 4.13 CI
2.02–8.47) and elevated LDH (OR 1.64 CI 1.07–2.52) and CRP (OR 2.56 CI 1.66–3.95) were associated with a cancer
diagnosis when adjusting for possible confounders. No single non-specific symptom was significantly associated with a
cancer diagnosis. One-year mortality for those diagnosed with cancer was 44.2%.
Conclusion: The prevalence of cancer matches that of another NSSC-CPP in Denmark. Deviations in basic biochemistry
were associated with a higher probability of underlying cancer and could possibly raise the level of suspicion of
malignancy among physicians. High one-year mortality was seen amongst patients diagnosed with cancer.
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Background
Fast track investigational courses for patients with sus-
pected cancer have been implemented in several European
countries [1–3]. In United Kingdom (UK) the 2-week wait
(2WW) referral systems was introduced in 2000, and in
Denmark organ-specific Cancer Patient Pathways (CPP’s)
were implemented in 2007 [2, 3]. Despite these efforts
British and Danish cancer patients suffer from low cancer
survival rates in comparison to other western countries
[4–8]. Not all cancer patients have benefitted from the
implementation of organ-specific CPPs [6, 7, 9, 10], and a
high proportion of malignancies have previously been di-
agnosed outside the CPPs [6, 11, 12]. One in every fourth
cancer patient present with non-organ specific symptoms
(e.g. pain, weight loss or fatigue) causing the general prac-
titioner to suspect a serious disease [11]. These patients
are not eligible for referral to organ-specific CPP’s.
Patients presenting with non-specific symptoms have a
longer time to diagnosis and lower survival rates com-
pared to patients presenting with organ-specific symptoms
[13]. Therefore a new CPP for patients with non-specific
symptoms and signs of cancer (NSSC-CPP) was imple-
mented in Denmark in 2012 [12, 14, 15]. The goal of the
NSSC-CPP was to ensure an accelerated investigational
course of no longer than 22 days, for patients presenting
with non-specific symptoms and signs of cancer [14].
Organ-specific symptoms, such as bleeding from the
intestinal tract and persisting digestive problems have
low predictive values of cancer [16–19], and some pa-
tients will experience warning symptoms without an
underlying cancer [20]. Whether non-specific symptoms
and other patient characteristics are related to a cancer
diagnosis in the NSSC-CPP setting, is yet unknown.
New tools are needed in the diagnostic process to deter-
mine which patients are at highest risk of having cancer.
No formal guidelines for the investigational course at
the NSSC-CPP have yet been made. As of now the diag-
nostic course includes blood tests and imaging as found
relevant by the physician in charge. The use of Computed
Tomography (CT) and Positron Emission Tomography,
with different tracers, in combination with CT (PET/CT)
have proven valuable in studies regarding fever of un-
known origin (FUO) and in the diagnostic process and
staging of several solid cancers [21–28]. The use of im-
aging in the NSSC-CPP setting has not yet been deter-
mined. Basic biomarkers such as haemoglobin, leukocytes,
thrombocytes, CRP and LDH have proven to have prog-
nostic value in many cancers, whereas their predictive
values have not yet been examined in the NSSC-CPP
setting [29–35].
Research in the NSSC-CPP setting has previously fo-
cused on the general practitioners (GP’s) part of the diag-
nostic process or on a limited number of patients. These
studies show that the GP’s gut feeling was a valuable
indicator of the likelihood of cancer, and found cancer
rates of 16–18% [36–38]. Finally the survival-rate in pa-
tients seen at the NSSC-CPP has not yet been determined.
The aim of this study was to describe the population re-
ferred to the NSSC-CPP and the investigational course,
estimate the prevalence of cancer and one-year mortality
and identify factors associated with a subsequent cancer
diagnosis in these patients with non-specific symptoms
and signs of cancer.
Methods
The study was a single centre cohort study on patients re-
ferred to the NSSC-CPP at a university hospital, North
Zealand Hospital (NOH), in the capital region of Denmark.
Study period covered from October 1st 2013 to September
30th 2014. Patient files were re-evaluated after one year;
files of patients with a cancer diagnosis were re-evaluated
one year after the time of diagnosis.
The NSSC-CPP setting in the capital region of Denmark
The population of Denmark is entitled to public health-
care benefits including free access to health-care. The
outpatient-clinic handling the NSSC-CPP at the University
Hospital, North Zealand Hospital (NOH) has a catchment
area of 310.000 citizens covering 19% of the capital region
of Denmark. Patients with non-organ-specific symptoms
and signs of cancer, who were healthy enough for an out-
patient course, were referred to the NSSC-CPP by their GP
and, or by other hospital departments. A predefined set of
blood samples and a chest x-ray was required before the
first visit. On basis of the information available at referral
the physician at the NSSC-CPP decided whether additional
testing, including imaging should be made before the pa-
tients attended their first visit. During first consultation
further investigations were planned. A coordinating nurse
and secretary made all appointments and arrangements,
and all patients were interviewed and examined by a sub-
group of specialists at the Department of Pulmonary and
Infectious Diseases, dedicated to the NSSC-CPP.
After a finalized investigational course the patient was
categorized into one of four groups i) cancer no longer sus-
pected (ICD10 codes (International Classification of Dis-
eases 10th Revision) DZ031 and ZZ5650), ii) cancer was
diagnosed and the patient was referred for treatment or
further diagnostic efforts at an organ-specific CPP, iii) Pa-
tient was still strongly suspected of having cancer and was
referred to an organ-specific CPP (ICD10 code DZ031XX),
iv) Patient was still suspected of having cancer, but not
found suitable for a fast track investigational course, or the
patient did not want further investigation at all.
Inclusion and exclusion
During the study period a list with the unique identifica-
tion number of every patient referred to the NSSC-CPP
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was created. Among those referred to NSSC-CPP, elec-
tronic patient files were checked to identify patients
above 18 years of age, with no new biopsy verified can-
cer at referral and with at least one visit at the NSSC-
CPP. Patients with a previous cancer diagnosis were
assessed both by the GP and the physician receiving the
referral and if their symptoms were not obviously related
to their prior cancer and they were found eligible by the
above mentioned criteria they were included in the
study. Patients were only included once.
Data collection
Data were collected retrospectively by review of the pa-
tient files (both paper forms and electronic files). Relevant
information of the course of investigation was collected;
i.e. symptoms, clinical findings, laboratory results, use of
imaging, findings by imaging, pathologic examinations,
endoscopies, concluding diagnoses and status at one-year
follow-up. The final diagnosis for those patients without
cancer diagnosis was defined as the diagnosis found most
likely to explain the patient’s symptoms. The decision
made by the investigating physician at NSSC-CPP, or by
the department taking over the investigational course after
the NSSC-CPP. Cancer diagnoses entered in the database
were any cancer diagnosis given within one year after
ended investigational course at the NSSC-CPP.
All diagnoses were crosschecked: The paper forms
filled out by the investigating physician was compared to
the electronic patient files and the Patient Index (where
the patients ICD-10 codes were listed). A standard oper-
ating procedure (SOP) was made. In order to ensure
standardization of the gathering and entering of data, all
complicated cases were gathered and discussed amongst
the study group and conclusions were entered in the
SOP. Information not available in the form filled out by
the investigating physician or in the electronic patient
files was recorded as missing.
Data were entered into a database using Epidata
(www.epidata.dk).
National guidelines on alcohol intake were used as cut
off value in terms of alcohol consumption [39]. ICD-10
codes DC00-DC97 were regarded as cancer diagnoses.
Concluding diagnoses and diagnoses at follow-up were
crosschecked in terms of correlation between the paper
files, the electronic patient files and the Patient Index
(where the patients ICD-10 codes were listed). Information
not available in the patient files was noted as missing.
Statistics
Chi-square (X2)/Fishers exact test and Wilcoxon rank-
sum test were used to identify differences in the distribu-
tion of characteristics between patients with and without a
cancer diagnosis. Data were presented as percentages
(counts) and means/medians (95% Confidence Interval
(CI)/inter quartile range (IQR)). Cancer probability was
presented as the percentage of included patients with a
cancer diagnosis or relapse of a previously diagnosed can-
cer within one year from ended investigational course at
the NSSC-CPP. Patients given the concluding diagnostic
codes DZ031 and ZZ5650 – cancer is no longer suspected,
by the NSSC-CPP, but who were subsequently diagnosed
with cancer (within one year), were regarded as cancers
not detected by the NSSC-CPP.
Logistic regression was used to find associations be-
tween cancer diagnosis and patient characteristics, symp-
toms and basic biochemistry abnormalities. Multivariate
analyses were adjusted by age, gender, smoking status and
alcohol consumption - covariates proven to have impact
on cancer risk in previous literature [40, 41]. Sensitivity
analyses were additionally adjusted by the variable ‘previ-
ously diagnosed cancer’. Additional sensitivity analyses ex-
amined the association of characteristics, symptoms and
basic biochemistry abnormalities with solid and haemato-
logical cancer diagnoses respectively. For haematological
cancer, patients with solid cancer and patients with no
cancer diagnosis were used as combined reference group.
For solid cancer patients with haematological cancer and
patients with no cancer diagnosis were used as a com-
bined reference group. Statistical significance level was set
at a P-value of <0.05.
Kaplan Meier curves were made to estimate one-year
survival and mortality in patients with a cancer diagnosis
and patients with no cancer diagnosis. Follow-up time
for patients with no subsequent cancer diagnosis started
at the conclusion of the diagnostic work-up. For patients
with at subsequent cancer diagnosis, follow-up started at
time of diagnosis.
SAS Enterprise Guide 7.1 was used for the statistical
analyses.
Ethics and approvals
This study was approved by the Danish Data Protection
Agency (j.nr. 2012–58-0004). Written informed consent
was not obtained from the human subjects do to the
retrospective design. Approval to go through patient files
were instead given by the Danish Health and Medicines
Authority (j.nr. 3–3013-1195/1/). Approval from the Da-
nish National Committee on Health Research Ethics was,
according to national guidelines, not needed as no bio-
medical intervention was performed.
Results
Study population
Eight hundred eighty-five patients were referred to the
NSSC-CPP at NOH during the study period and 825(93%)
were included in the study (Fig. 1).
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Patient characteristics
The median age was 67 (IQR 55–75) years and 47.4%
were male. The population was primarily referred to the
NSSC-CPP from a GP (75.4%). Current or former smok-
ing was reported in 65.8% and 9.5% had a weekly alcohol
consumption level above national guidelines. Cardiovas-
cular disease (15.6%), lung disease (13.3%) and previ-
ously diagnosed cancer (12.2%) were the most common
comorbidities.
One year after ended diagnostic course at the NSSC-CPP
16.7% (138) of the patients had been diagnosed with cancer.
Patients diagnosed with cancer were significantly older and
more often previously diagnosed with cancer (Table 1).
Weight loss (cancer group 39%, no-cancer group 42%),
fatigue (cancer group 35% no-cancer group 39%) and loss
of appetite (cancer group 28%, no-cancer group 26%) were
the most common symptoms in both groups. No single
symptom was significantly more or less pronounced in the
cancer group (data not shown).
Objective findings were inconsistently reported or per-
formed (Rectal exploration: 22%, breast examination:
60% of all women, auscultation: 82%, abdominal examin-
ation: 78%, lymph nodes: 82%, data not shown).
The investigational course
The duration of the diagnostic course at the NSSC-CPP
was a median of 9 days (IQR 1–15), and patients had a
median of 2 visits (IQR 1–2). During the investigational
course 76.7% of the patients went through advanced
imaging (CT, FDG-PET/CT, Ultrasound or Magnetic
Resonance Imaging (MRI)). FDG-PET/CTs and CTs were
the preferred type of imaging, used in 30.4% and 39.0%
of the investigational courses respectively. FDG-PET/CTs
more often in patients subsequently diagnosed with
cancer (Table 2).
The abnormal biochemistry levels seen most often
were elevated ESR in 52.4% followed by elevated LDH in
32.8% and elevated CRP in 30.5%. Few patients had
leukocytopenia (2.6%) and thrombocytopenia (5.9%). Ab-
normalities in basic biochemistry were seen more often
in the cancer group.
Bone marrow examinations were performed in 13.3%
of the investigational courses, most often in patients
with a subsequent cancer diagnosis (Table 2).
Outcome and mortality
Overall 16.7% (138) were diagnosed with cancer within
one year from finalized diagnostic course at the NSSC-
CPP, of those 8% represented a relapse of a previously
diagnosed cancer. Time to registration of a cancer diag-
nosis was a median of 22 days (IQR 10–45) from date of
first visit. Among the 138 patients who were diagnosed
with cancer 70.3% had a solid cancer and 29.7% had
haematological cancer. Gastro intestinal cancer (23.2%)
and lung cancer (10.1%) were the most frequent solid
cancers. In patients with no subsequent cancer diagnosis
the most frequent diagnoses were rheumatic (12.4%),
gastrointestinal (10.3%), haematological (8.7%) and infec-
tious (3.5%).
In 9 patients the cancer diagnosis was not detected by
the NSSC-CPP. Diagnoses in those 9 patients were as
following; bile duct cancer, hepatocellular cancer, baso-
cellular skin cancer, relapse of prostate cancer, ovarian
cancer with metastasis, rectal cancer, salivary duct can-
cer and breast cancer.
One-year mortality in patients diagnosed with cancer
or relapse of cancer was 44.2% and 3.3% for those with
no cancer diagnosis (Fig. 2). A sensitivity analysis omit-
ting patients with a previously diagnosed cancer did not
change the one-year mortality (data not shown).
Predictors of cancer
Univariate
Age was significantly associated with a cancer diagnosis
(OR 1.03, 95%CI 1.01–1.04), with a 34% increase in
odds with every ten-year increase in age. No other
patient characteristic or single symptom was signifi-
cantly associated with a cancer diagnosis. Anemia
(OR 1.56, 95%CI 1.05–2.31), leukocytopenia (OR 3.45,
95%CI 1.15–10.39), leukocytosis (OR 2.38, 95%CI 1.62–
3.50), thrombocytopenia (OR 3.47, 95%CI 1.77–6.81),
Fig. 1 Inclusions and exclusions. 1NSSC-CPP= cancer patient pathway
for patients with nonspecific symptoms and signs of cancer
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Table 1 Characteristic in patients with and without cancer, P-value representing a test for difference
Variable All Cancera No-cancera P-value
% (N) 100 (825) 16.7 (138) 83.3 (687)
Referred by
General practice 75.4 (605) 74.6 (97) 75.6 (508) 0.851
Hospital department 20.1 (161) 21.5 (28) 19.8 (133)
Other 4.5 (36) 3.8 (5) 4.6 (31)
Gender
Male 47.4 (391) 44.2 (61) 48.0 (330) 0.411
Age
median (IQR) 67 (55–75) 69 (62–76) 67 (53–74) 0.003
Groups
18–39 years 7.5 (62) 3.6 (5) 8.3 (57) 0.050
40–54 years 17.1 (141) 10.9 (15) 18.3 (126)
55–69 years 33.0 (272) 36.2 (50) 32.3 (222)
70–79 years 31.0 (256) 36.2 (50) 30.0 (206)
≥ 80 years 11.4 (94) 13.0 (18) 11.1 (76)
Body mass index
median (IQR) 24.3 (21.7–28.0) 23.4 (21.9–26.8) 24.5 (21.7–28.1) 0.317
Smoking status
Never 34.2 (271) 29.6 (40) 35.1 (231) 0.222
Former/current 65.8 (522) 70.4 (95) 64.9 (427)
Package years median (IQR)b 25 (15–40) 30 (14–40) 25 (15–40) 0.818
Alcohol consumption per week
Units per week, median (IQR)c 5 (0–14) 7 (0–14) 4 (0–14) 0.378
Alcohol consumption above recommendationsd 9.5(69) 11.3 (13) 9.1 (56) 0.466
Chronic diseases at first visit
Lung disease 13.3 (110) 10.1 (14) 14.0 (96) 0.227
Cardiovascular diseases 15.6 (129) 11.6 (16) 16.4 (113) 0.152
Cerebrovascular diseases 10.8 (89) 12.3 (17) 10.5 (72) 0.525
Diabetes 11.6 (96) 8.7 (12) 12.2 (84) 0.238
Inflammatory diseases 11.9 (98) 7.2 (10) 12.8 (88) 0.065
Renal failure 4.1 (34) 2.2 (3) 4.5 (31) 0.207
Peptic ulcer 3.2 (26) 3.6 (5) 3.1 (21) 0.788
Cirrhosis 0.4 (3) 0.7 (1) 0.3 (2) 0.423
Dementia 1.8 (15) 0 2.2 (15) 0.152
Previously diagnosed cancer 12.2 (101) 21.7 (30) 10.3 (71) <0.001
Number of chronic diseases
0 46.3 (382) 44.9 (62) 46.6 (320) 0.054
1–2 46.3(382) 52.2 (72) 45.1 (310)
≥ 3 7.4 (61) 2.9 (4) 8.3 (57)
Data presented as percentages (counts) unless otherwise indicated. Chi square-test or Fishers exact test for 2 × 2 tables, Students T-test for normally distributed
data, otherwise Wilcoxon’s Rank Sum Test. aCancer or no-cancer within one year after ended investigational course. bIn current or former smokers only. cOne
unit = 15 ml of alcohol. dRecommendations = national guidelines. Less than 5% missing values in every variable except for Body Mass Index (32.5%), Package years
(12.8%) and alcohol consumption (11.8%)
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thrombocytosis (OR 1.89, 95%CI 1.16–3.07) and elevated
ESR (OR 1.82, 95%CI1.05–3.15), CRP (OR 2.70, 95%CI
1.84–3.97) and LDH (OR 1.90, 95%CI 1.30–2.79) were
significantly associated with a cancer diagnosis in a univar-
iate analysis (Table 3).
Multivariate
When adjusting for age, gender, smoking status and al-
cohol consumption, anemia (OR 1.63, 95%CI 1.02–2-60),
leukocytosis (OR 2.06, 95%CI 1.34–3.15), thrombocytopenia
(OR 4.13, 95%CI 2.02–8.47), elevated LDH (OR 1.64, 95%CI
1.07–2.52) and CRP (OR 2.56, 95%CI 1.66–3.95) were
still significantly associated with a cancer diagnosis. Age
continued to be associated with a cancer diagnosis when
adjusting for gender, smoking status and alcohol consump-
tion (Table 3). Sensitivity analyses additionally adjusting for
previously diagnosed cancer did not change the results of
the multivariate analyses (data not shown).
In a sensitivity analysis anemia (OR 2.36, 95%CI 1.09–
5.08), leukocytopenia (OR 6.98, 95%CI 1.69–28.69) and
thrombocytopenia (OR 7.80, 95%CI 3.19–19.10) were sig-
nificantly associated with a haematological cancer diagno-
sis when adjusting for possible confounders. Leukocytosis
(OR 2.19, 95%CI 1.35–3.55), Thrombocytosis (OR 1.93,
95%CI 1.06–3.51) and CRP (OR 2.91, 95%CI 1.76–4.80)
were associated with a solid cancer diagnosis (Table 4).
Discussion
Main findings
Eight hundred twenty-five patients were seen at the
NSSC-CPP during the study period with a cancer preva-
lence of 16.7%. Solid cancers were seen in 70.3%; gastro
intestinal and lung cancer being the most common types.
Abnormal basic biochemistry levels including anemia,
leucocytosis, thrombocytopenia and elevated LDH and
CRP were significantly associated with a cancer diagnosis
when adjusting for possible confounders. In a sensitivity
analysis we found cytopenia (anemia, leukopenia and
thrombocytopenia) to be significantly associated with
haematological cancer, leucocytosis, thrombocytosis and
elevated CRP were associated with solid cancer. Patients
diagnosed with cancer had a one-year mortality of 44.2%.
Table 2 Investigational course, P-value representing a test for difference
All Cancera No-cancera P-value
N = 825 N = 138 N = 687
Length of investigational course in days median (IQR)b 9 (1–15) 10 (1–16) 9 (1–15) 0.699
Number of visits at the NSSC-CPP median (IQR) 2 (1–2) 2 (1–2) 2 (1–2) 0.960
Diagnostic imaging used during or prior to the investigational course %(n)
CT 39.0 (322) 42.8 (59) 38.3 (263) 0.326
FDG-PET/CT 30.4 (251) 38.4 (53) 28.8 (198) 0.026
Ultrasound 16.0 (132) 10.9 (15) 17.0 (117) 0.072
MRI 5.3 (44) 2.9 (4) 5.8 (40) 0.163
No advanced imaging 23.3 (192) 22.5 (31) 23.4 (161) 0.805
Pathological examinations and endoscopies performed during investigational course %(n)
Bone marrow 13.3 (110) 21.7 (30) 11.6 (80) 0.002
Lymph node extirpation 2.8 (23) 9.4 (13) 1.5 (10) <0.001
Lower endoscopyc 9.9 (82) 8.0 (11) 10.3 (71) 0.397
Upper endoscopyc 9.6 (79) 5.0 (7) 10.5 (72) 0.049
aCancer or no-cancer within one year after ended diagnostic examination, bFrom date of first visit, cWith or without biopsy. There are less than 5% missing values
in every variable except for LDH (5.6%) and Erythrocyte Sedimentation Ratio (48.8%)
Fig. 2 Survival at one-year follow-up. 1Risk time: one year from ended
work-up at the NSSC-CPP for patients with no subsequent cancer but
one year from time of diagnosis for patients with a subsequent cancer
diagnosis. NSSC-CPP = cancer patient pathway for patients with
non-specific symptoms and signs of cancer
Jørgensen et al. BMC Cancer  (2017) 17:809 Page 6 of 11
Patient characteristics
Characteristics of the two groups – cancer and no can-
cer were surprisingly identical in terms of gender, smok-
ing status and alcohol consumption. Patients referred to
the NSSC-CPP were equally ill in terms of comorbidities
and symptoms, with the exception of previously diag-
nosed cancer. Similar findings have been reported by
Ingeman et al. who also found weight loss, fatigue and
loss of appetite to be the most common symptoms [36],
which obviously relates to the fact, that the NSSC-CPP
was designed for patients with these symptoms. The
equality in comorbidity burden and in symptom presen-
tation might reflect that both groups represented com-
plicated cases where the GP had had trouble finding the
right time and place for referral.
Investigational course
PET/CT (using different tracers) and CT have been
recognised as useful tools in diagnosing and staging of
many solid cancers and in the FUO-setting [21–28] and
FDG-PET/CT’s and CT’s were also the most common
choice of imaging in this study. In 23.3% of the patients
no advanced imaging was made. This may partly be ex-
plained by bone marrow examination being the examin-
ation of choice in patients with suspected haematological
illness. Determining the usefulness of systematic use of
imaging in the setting of the NSSC-CPP in a prospective
study is needed.
The length of the investigational course from first visit
were a median of 9 days (IQR 1–15). Diagnostic imaging
was usually performed before attending first visit at the
NSSC-CPP, and the subsequent assessment required a
median of merely 2 visits with a specialist, indicating
that this type of fast track evaluation is possible. In
addition, a substantial effort was made before and be-
tween visits by the coordinating nurse and the physician
at interdisciplinary conferences and through evaluation
of interim test results.
Clinical findings were inconsistently reported. To learn
more about the diagnostic yield of different
Table 3 Predictors of cancer diagnosis within one-yeara
Unadjusted analysis Adjusted analysisb
OR (95%CI) P-value OR (95% CI) P-value
Age in years 1.03 (1.01–1.04) <0.001 1.03 (1.01–1.04) 0.002
Gender male 0.86 (0.59–1.24) 0.414 – –
Alcohol consumption above guidance 1.27 (0.67–2.40) 0.467 – –
Former/current smoker yes 1.29 (0.86–1.92) 0.223 – –
Symptoms
Weight loss 0.89 (0.61–1.31) 0.549 – –
Fatigue 0.83 (0.56–1.23) 0.348 – –
Loss of appetite 1.11 (0.73–1.68) 0.626 – –
Abdominal pain 1.39 (0.88–2.18) 0.158 – –
Indefinable pain 1.18 (0.75–1.87) 0.479 – –
Night sweats 0.63 (0.37–1.08) 0.092 – –
General illness 0.86 (0.50–1.45) 0.560 – –
Fever 0.50 (0.21–1.18) 0.114 – –
Other 1.24 (0.72–2.16) 0.440 – –
Abnormal biochemistry levels
Anemia <7.3 for women
<8.3 for men
1.56 (1.05–2.31) 0.028 1.63 (1.02–2.60) 0.040
Leucocytopenia <3.5 × 109 3.45 (1.15–10.39) 0.028 2.01 (0.52–7.74) 0.311
Leucocytosis >8.8 × 109 2.38 (1.62–3.50) <0.001 2.06 (1.34–3.15) <0.001
Thrombocytopenia <145 × 109 3.47 (1.77–6.81) <0.001 4.13 (2.02–8.47) <0.001
Thrombocytosis >390 × 109 1.89 (1.16–3.07) 0.010 1.67 (0.96–2.91) 0.071
Elevated ESRc >15 1.82 (1.05–3.15) 0.033 1.29 (0.70–2.37) 0.411
Elevated LDHd > 205 U/l 1.90 (1.30–2.79) 0.001 1.64 (1.07–2.52) 0.023
Elevated CRPe >10 mg/l 2.70 (1.84–3.97) <0.001 2.56 (1.66–3.95) <0.001
aWithin one year of ended investigational course at the NSSC-CPP bMultivariate analysis adjusted for age, gender, smoking status and alcohol consumption. cESR
Erythrocyte Sedimentation Ratio. dLDH Lactate dehydrogenase. eCRP C-reactive protein
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investigations, there is a need for prospective and sys-
tematic assessment of these patients.
Cancer prevalence and mortality
A cancer prevalence of 16.7% is similar to other studies
previously examining patients referred to or seen by the
NSSC-CPP and finding a cancer prevalence of 16 to
18%, these two studies from the same region of
Denmark partly included the same patients [36, 37]. One
could argue that this percentage is low, compared to the
organ specific CPP’s, with cancer prevalences of 27–30%
[42]. An increasing proportion of patients continues to
be referred to the NSSC-CPP, it is likely that the cancer
prevalence will be reduced slightly. In previous studies
as well as ours lung, gastrointestinal and haematological
cancers were the most common cancer diagnoses, we
however found a higher prevalence of haematological
cancer [36, 37]. This could indicate that a high level of
suspicion was required in the NOH setting for patients
to access the haematological CPP. The most common
non-malignant diagnoses were rheumatic, gastrointes-
tinal, non-malignant haematological or infectious (in
that order). This matches to some extend findings from
a previous study [37].
The one-year mortality of 44.2% in patients with a
cancer diagnosis is high considering the short investiga-
tional course with no unreasonable delays and is not in
line with the aim of finding the cancer diagnoses at
curable stages [14, 43]. In comparison the overall
one-year mortality for all cancer types between 2009
and 2013 were 23% [44]. Experiences from the organ-
specific CPP’s and the UK 2WW-referral system have
shown that cancers were not convincingly found at
earlier stages after the implementation of these path-
ways [4–8, 43]. This might also be the case with the
NSSC-CPP. A previous study found that patients with
non-specific symptoms had a long course leading up
to the referral to the NSSC-CPP [36]. Evidently both
Table 4 Sensitivity analysis - Predictors of solid and haematological cancer within one-yeara
Haematological cancer Solid cancer
Unadjusted analysis Adjusted analysisb Unadjusted analysis Adjusted analysisb
OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value
Age in years 1.02 (0.99–1.05) 0.069 – – 1.02 (1.01–1.04) 0.006 1.02 (1.01–1.04) 0.014
Gender male 1.30 (0.69–2.44) 0.411 – – 0.72 (0.47–1.11) 0.133 – –
Alcohol consumption above guidance 0.92 (0.27–3.09) 0.894 – – 1.40 (0.69–2.87) 0.351 – –
Former/current smoker yes 0.92 (0.47–1.81) 0.816 – – 1.46 (0.91–2.35) 0.120 – –
Symptoms –
Weight loss 0.56 (0.27–1.14) 0.109 – – 1.09 (0.70–1.69) 0.698 – –
Fatigue 0.80 (0.41–1.58) 0.522 – – 0.86 (0.55–1.35) 0.511 – –
Loss of appetite 0.31 (0.11–0.88) 0.028 0.17 (0.04–0.71) 0.015 1.63 (1.03–2.57) 0.036 1.52 (0.93–2.50) 0.097
Abdominal pain 0.36 (0.11–1.19) 0.094 – – 1.99 (1.22–3.25) 0.006 2.39 (1.42–4.06) 0.001
Indefinable pain 1.50 (0.72–3.16) 0.281 – – 1.03 (0.59–1.78) 0.926 – –
Night sweats 0.34 (0.10–1.13) 0.079 – – 0.81 (0.45–1.44) 0.465 – –
General illness 0.43 (0.13–1.40) 0.159 – – 1.09 (0.61–1.94) 0.769 – –
Fever 0.61 (0.14–2.58) 0.499 – – 0.48 (0.17–1.36) 0.169 – –
Other 0.86 (0.29–2.46) 0.771 – – 1.41 (0.76–2.59 0.276 – –
Basic Biochemistryc
Anemia 2.72 (1.43–5.18) 0.002 2.36 (1.09–5.08) 0.029 1.11 (0.69–1.78) 0.669 – –
Leukopenia 11.69 (3.69–37.00) <0.001 6.98 (1.69–28.69) 0.007 –d 0.987 – –
Leukocytosis 1.26 (0.62–2.59) 0.521 – – 2.76 (1.79–4.26) <0.001 2.19 (1.35–3.55) 0.001
Thrombocytopenia 6.52 (2.83–15.01) <0.001 7.80 (3.19–19.10) <0.001 1.53 (0.62–3.76) 0.359 – –
Thrombocytosis 0.85 (0.29–2.48) 0.767 – – 2.27 (1.35–3.84) 0.002 1.93 (1.06–3.51) 0.032
Elevated ESRe 1.26 (0.49–3.21) 0.622 – – 2.02 (1.06–3.87) 0.033 1.35 (0.66–2.75) 0.406
Elevated LDHf 1.64 (0.86–3.15) 0.137 – – 1.88 (1.21–2.93) 0.005 1.51 (0.92–2.48) 0.100
Elevated CRPg 1.63 (0.84–3.14) 0.147 – – 3.00 (1.93–4.67) <0.001 2.91 (1.76–4.80) <0.001
aWithin one year of ended investigational course at the NSSC-CPP bMultivariate analysis adjusted for age, gender, smoking status and alcohol consumption. cReferences
are given in Table 3. dLeukopenia were so rarely seen in patients with solid cancer making it impossible to estimate OR. eESR Erythrocyte Sedimentation Ratio. fLDH
Lactate dehydrogenase. gCRP C-reactive protein
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patient and doctors delays may adversely affect the
potential effect of the NSSC-CPP on cancer survival.
Predictors of cancer
Age was found to have a strong association with a can-
cer diagnosis which is well known [36, 37, 40].
No single non-specific symptom was significantly asso-
ciated with a cancer diagnosis. Even organ-specific symp-
toms are known to have low predictive values of cancer
making it unlikely for non-specific symptoms to be highly
predictive. Non-specific symptoms are seen very often by
the GP and most often in patients with no underlying
cancer and the threshold for referring patients is still
unknown [11, 16–19]. More experience and knowledge
about events prior to referral may provide us with better
tools to differentiate who to refer and who not to refer.
Our results suggest that deviations in basic biochemis-
try levels could be useful predictors of cancer. In line
with this Bislev et al. found anemia and elevated alkaline
phosphatases associated with a cancer diagnosis in the
NSSC-CPP [37]. Basic biochemistry levels are prognostic
(and not diagnostic) factors in many specific cancers and
might be indicative of advanced stages of cancer and
higher risk of deadly outcome [29–35]. In this cohort
many cancer patients were seen with abnormal levels in
basic biochemistry and a high mortality indicating that
these patients despite efforts are diagnosed in advanced
stages of their disease. Abnormal levels in basic bio-
chemistry should raise awareness by the GP or investi-
gating physician if there are no other reasonable causes
explaining these deviations.
The association of non-specific symptoms and bio-
chemistry factors with cancer diagnosis may vary be-
tween patients with and without comorbidities, as some
of these comorbidities might explain some symptoms
and abnormal biochemistry levels. This is however not
within the scope of this study but would be addressed in
future prospective studies.
According to national guidelines cytopenia in two or
three cell-lines is regarded as criteria for referral to a haem-
atological CPP [45–48]. Results of the sensitivity analysis
showed that anemia, leukocytopenia or thrombocytopenia
were suggestive of a haematological cancer diagnosis,
supporting the guidelines of referral to the haemato-
logical CPP.
Strengths and limitations
The retrospective design in a clinical set-up with phys-
ician driven decisions caused high numbers of missing
values in objective examinations. This could have caused
an overestimation of effects, and was handled by not in-
cluding objective findings in the analysis of association
with cancer and by simply describing the use of and
findings by imaging. Comorbidities could also have been
insufficiently reported in the patient files leading to an
underestimation of the effect of comorbidities. Report-
ings of comorbidities were however unlikely to have
been unevenly distributed in the two groups. Informa-
tion registered in the patient files might have been mis-
interpreted, as the information was not collected with
the sole purpose of this study.
Due to the retrospective design it was difficult in this
study to assess which patients were most likely to develop
a cancer diagnosis. In order to identify high risk and low
risk patients in this group with otherwise non-specific
symptoms, prospective studies are needed - preferably
multicentre studies including collaboration with GPs in
order to assess the prevalence of risk factors and predict
the risk of cancer.
A major strength was the population size with 825 in-
cluded patients. Patients were unselected thus describing
the everyday clinical situation, including patients re-
ferred both from the GP, specialist medical practitioners
and hospital departments. Broad inclusions make the re-
sults of this study generalizable to the clinical practice at
the NSSC-CPP and in part to the referring units.
Patients were followed for an entire year from time of
cancer diagnosis, giving an excellent follow-up and mak-
ing it possible to estimate one-year mortality. Diagnoses
were crosschecked both in paper files, electronic patient
files and in the patient index, rather than relying on reg-
isters accuracy, thus ensuring a strong link between the
investigational course and the diagnosis found to be the
most likely cause of symptoms. The collection of data
furthermore led to another study exploring quality of life
in patients referred to NSSC-CPP [49].
Conclusion
The prevalence of cancer in patients seen at the NSSC-
CPP is substantial. Non-specific symptoms should raise
awareness in the general population and by the GP even
though no single symptom was associated with cancer.
Anemia, leukocytosis, thrombocytopenia and elevated
LDH and CRP should raise clinical concern in patients
with non-specific symptoms where the suspicion of
cancer has been raised, and could possibly guide the
physician towards the most likely diagnosis and the best-
suited investigational course. An alarmingly high one-
year mortality of 44% in this population suggests that
cancer diagnoses were found at late stages. Larger and
prospective studies are needed to identify combinations
of symptoms, findings and biochemistry related to a
cancer diagnoses, hopefully making it possible to find
cancer diagnoses in these patients at earlier stages.
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